{'fraction_non_alphanumeric': 0.038314176245210725, 'fraction_numerical': 0.007662835249042145, 'mean_word_length': 5.6440677966101696, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
ERK-activated kinase RSK2 protects against inflammatory arthritis-induced bone destruction by opposing the tumour necrosis factor α-mediated inhibition of bone formation

Local destruction of cartilage and bone of joints followed by systemic osteopenia characterise rheumatoid arthritis (RA). Proinflammatory cytokines like interleukin β (ILβ) and tumour necrosis factor α (TNFα) known to activate all major mitogen-activated protein kinases (MAPKs; extracellular signal-regulated kinases (ERKs), c-Jun-N-terminal kinases (JNKs) and p38) are key players in RA. Using human tumour necrosis factor transgenic (hTNFtg) mice as a model for inflammatory arthritis, we have already characterised the role of JNK1 and p38α in regulating TNFα-induced arthritis. We now investigate the role …